Wells Fargo & Company Mi Nk Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 11,017 shares of INKT stock, worth $9,584. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,017
Previous 11,526
4.42%
Holding current value
$9,584
Previous $12,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding INKT
# of Institutions
37Shares Held
939KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA234KShares$203,7380.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$144,9990.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny105KShares$91,5480.0% of portfolio
-
Geode Capital Management, LLC Boston, MA88.9KShares$77,3040.0% of portfolio
-
Black Rock Inc. New York, NY76.1KShares$66,2480.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $29.4M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...